A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases

Tombal, Bertrand; Saad, Fred; Gallardo, Enrique; Soares, Andrey; Loriot, Yohann; McDermott, Ray; Briers, Erik; Lagström, Mikael; Coens, Corneel; Poncet, Coralie; Fournier, Beatrice; Gillessen, Silke

doi:10.1080/14796694.2025.2592722

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases

Tombal, Bertrand

;

Saad, Fred

;

Gallardo, Enrique

;

Soares, Andrey

;

Gillessen, Silke

;et.al.

(2025) Future Oncology — Vol. 21, n° 30, p. 3845-3858 (2025)

Files

No attached file found for this publication.

Details

Authors

Tombal, BertrandUCLouvain
Author
Saad, Fred
Author
Gallardo, Enrique
Author
Soares, Andrey
Author
Gillessen, Silke
Author

Affiliations

UCLouvainSSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation

Citations

APA
Chicago
FWB

Tombal, B., Saad, F., Gallardo, E., Soares, A., Loriot, Y., McDermott, R., Briers, E., Lagström, M., Coens, C., Poncet, C., Fournier, B., & Gillessen, S. (2025). A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases. Future Oncology, 21(30), 3845-3858. https://doi.org/10.1080/14796694.2025.2592722 (Original work published 2025)